Literature DB >> 2416957

Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

B Blondel, R Crainic, O Fichot, G Dufraisse, A Candrea, D Diamond, M Girard, F Horaud.   

Abstract

Antigenic variants resistant to eight neutralizing monoclonal antibodies were selected from wild (Mahoney) and attenuated (Sabin) type 1 infectious poliovirions. Cross-immunoprecipitation revealed interrelationships between epitopes which were not detected by cross-neutralization. Operational analysis of antigenic variants showed that seven of eight neutralization epitopes studied were interrelated. Only one neutralization epitope, named Kc, varied independently from all the others. This latter, recognized by C3 neutralizing monoclonal antibody, was present not only on infectious virions but also on heat-denatured (C-antigenic) particles and on isolated capsid protein VP1. Loss of the neutralization function of an epitope did not necessary result from the loss of its antibody-binding capacity. Such potential, but not functional, neutralization epitopes exist naturally on Mahoney and Sabin 1 viruses. Their antibody-binding property could be disrupted by isolating antigenic variants in the presence of the nonneutralizing monoclonal antibody and anti-mouse immunoglobulin antibodies. Single-point mutations responsible for the acquisition of resistance to neutralization in the antigenic variants were located by sequence analyses of their genomes. Mutants selected in the presence of C3 neutralizing monoclonal antibody always had the mutation located inside the antibody-binding site (residues 93 through 103 of VP1) at the amino acid position 100 of VP1. On the contrary, antigenic variants selected in the presence of neutralizing monoclonal antibodies reacting only with D-antigenic particles had mutations situated in VP3, outside the antibody-binding site (residues 93 through 103 of VP1). The complete conversion of the Mahoney to the Sabin 1 epitope map resulted from a threonine-to-lysine substitution at position 60 of VP3.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2416957      PMCID: PMC252701     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

3.  Advantages and disadvantages of killed and live poliomyelitis vaccines.

Authors:  J L Melnick
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

Review 4.  Antigenic characterization of viruses by monoclonal antibodies.

Authors:  J W Yewdell; W Gerhard
Journal:  Annu Rev Microbiol       Date:  1981       Impact factor: 15.500

5.  Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome.

Authors:  V R Racaniello; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

6.  Primary structure, gene organization and polypeptide expression of poliovirus RNA.

Authors:  N Kitamura; B L Semler; P G Rothberg; G R Larsen; C J Adler; A J Dorner; E A Emini; R Hanecak; J J Lee; S van der Werf; C W Anderson; E Wimmer
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

7.  [Structural polypeptide VP1 in poliovirus type 1 induced by neutralizing antibodies].

Authors:  B Blondel; R Crainic; F Horodniceanu
Journal:  C R Seances Acad Sci III       Date:  1982-01-11

8.  Determination of type 1 poliovirus subtype classes with neutralizing monoclonal antibodies.

Authors:  R Crainic; P Couillin; N Cabau; A Boue; F Horodniceanu
Journal:  Dev Biol Stand       Date:  1981

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Poliovirus neutralization epitopes: analysis and localization with neutralizing monoclonal antibodies.

Authors:  E A Emini; B A Jameson; A J Lewis; G R Larsen; E Wimmer
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

View more
  39 in total

Review 1.  Protein antigenicity.

Authors:  M H Van Regenmortel
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

2.  High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus.

Authors:  J C de la Torre; C Giachetti; B L Semler; J J Holland
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

3.  Molecular basis for linkage of a continuous and discontinuous neutralization epitope on the structural polypeptide VP2 of poliovirus type 1.

Authors:  K J Wiegers; K Wetz; R Dernick
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

4.  Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants.

Authors:  J C Saiz; M J Gonzalez; M V Borca; F Sobrino; D M Moore
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range.

Authors:  Jaume Jorba; Ray Campagnoli; Lina De; Olen Kew
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

6.  Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles.

Authors:  F Delpeyroux; E Van Wezel; B Blondel; R Crainic
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Very high frequency of reversion to guanidine resistance in clonal pools of guanidine-dependent type 1 poliovirus.

Authors:  J C de la Torre; E Wimmer; J J Holland
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

8.  Antigenic modification of polioviruses by host proteolytic enzymes.

Authors:  M Roivainen; A Huovilainen; T Hovi
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

9.  Molecular pathogenesis of type 2 poliovirus in mice.

Authors:  T Couderc; B Guinguene; F Horaud; A Aubert-Combiescu; R Crainic
Journal:  Eur J Epidemiol       Date:  1989-09       Impact factor: 8.082

10.  A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses.

Authors:  Diana Kouiavskaia; Zhaochun Chen; Eugenia Dragunsky; Olga Mirochnitchenko; Robert Purcell; Konstantin Chumakov
Journal:  J Clin Virol       Date:  2015-02-03       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.